It takes several years of hard work to become an overnight success. Or so they say.
Everything around the breast cancer biotech drug trastuzumab smacks of this. After 19 years on the market, it is still one of the top-selling drugs for Roche, adding more than $30 billion in sales in just last five years. It will earn handsome revenues for Biocon in about a year from now. The final door to that market opened on 1 December when the Food and Drug Administration approved Biocon and its marketing partner Mylan’s Ogivri, trastuzumab biosimilar to Roche’s drug, for sale in the US market.